Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Lubricin-inspired Osteoarthritis Treatment: a Unique Solution

NCT: NCT07611708 · NOT_YET_RECRUITING

NCT IDNCT07611708
StatusNOT_YET_RECRUITING
Start Date2026-08
Completion2027-12

Brief Summary

This goal of this open label study is to evaluate the safety and tolerability of a single intra-articular administration of ABR1 in adults with knee osteoarthritis with a KL grade from 2 to 4. The primary questions it aims to answer are: 1. Is ABR1 safe to use as an intraarticular injection for participants with knee osteoarthritis? 2. What medical problems do participants have after receiving a single injection of ABR1? Participants will receive a single injection of ABR1 to the knee with osteoarthritis. Participants will 1. Keep a stable pain treatment regimen 2. Visit the clinic at 1 week, 4 weeks, 8 weeks, and 12 weeks post injection 3. Keep a diary of their symptoms and number of times they use a rescue medication for their knee pain.

Frequently Asked Questions

What is Lubricin-inspired Osteoarthritis Treatment: a Unique Solution?

Lubricin-inspired Osteoarthritis Treatment: a Unique Solution is a clinical trial registered under NCT07611708. Current status: NOT_YET_RECRUITING.

What is the status of NCT07611708?

The current status of NCT07611708 (Lubricin-inspired Osteoarthritis Treatment: a Unique Solution) is: NOT_YET_RECRUITING.

When did Lubricin-inspired Osteoarthritis Treatment: a Unique Solution start?

Lubricin-inspired Osteoarthritis Treatment: a Unique Solution started on 2026-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.